Chapter 1 - The Nursing Process and Drug Therapy _____________________ 3
| | | | | | | |
Chapter 2 - Pharmacologic Principles _________________________________ 7
| | | |
Chapter 3 - Lifespan Considerations _________________________________ 13
| | | |
Chapter 4 - Cultural Legal and Ethical Considerations ___________________ 19
| | | | | | |
Chapter 5 - Medication Errors Preventing and Responding _______________ 25
| | | | | | |
Chapter 6 - Patient Education and Drug Therapy _______________________ 29
| | | | | | |
Chapter 7 - Over-the-Counter Drugs and Herbal and Dietary
| | | | | | | |
| Supplements 34 | | Chapter 8 - Gene Therapy and Pharmacogenomics ____ 38 | | | | | |
Chapter 9 - Photo Atlas of Drug Administration ________________________ 42
| | | | | | |
Chapter 10 - Analgesic Drugs ______________________________________ 50
| | | |
Chapter 11 - General and Local Anesthetics ___________________________ 57
| | | | | |
Chapter 12 - Central Nervous System Depressants and Muscle
| | | | | | | |
| Relaxants 61 | | Chapter 13 - Central Nervous System Stimulants and Related
| | | | | | | |
| Drugs _________________________________________________________ 66
Chapter 14 - Antiepileptic Drugs ____________________________________ 70
| | | |
Chapter 15 - Anti-Parkinson Drugs___________________________________ 75
| | | |
Chapter 16 - Psychotherapeutic Drugs _______________________________ 80
| | | |
Chapter 17 - Substance Use Disorder ________________________________ 87
| | | | |
Chapter 18 - Adrenergic Drugs ______________________________________ 92
| | | |
Chapter 19 - Adrenergic-Blocking Drugs ______________________________ 97
| | | |
Chapter 20 - Cholinergic Drugs _____________________________________ 102
| | | |
Chapter 21 - Cholinergic-Blocking Drugs ______________________________ 107
| | | |
Chapter 22 - Antihypertensive Drugs _________________________________ 112
| | | |
Chapter 23 - Antianginal Drugs _____________________________________ 118
| | | |
Chapter 24 - Heart Failure Drugs ____________________________________ 124
| | | | |
Chapter 25 - Antidysrhythmic Drugs _________________________________ 129
| | | |
Chapter 26 - Coagulation Modifier Drugs ______________________________ 134
| | | | |
Chapter 27 - Antilipemic Drugs _____________________________________ 140
| | | |
Chapter 28 - Diuretic Drugs ________________________________________ 145
| | | |
Chapter 29 - Fluids and Electrolytes _________________________________ 151
| | | | |
,Chapter 30 - Pituitary Drugs ________________________________________ 157
| | | |
Chapter 31 - Thyroid and Antithyroid Drugs____________________________ 161
| | | | | |
Chapter 32 - Antidiabetic Drugs _____________________________________ 166
| | | |
Chapter 33 - Adrenal Drugs ________________________________________ 174
| | | |
Chapter 34 - Women’s Health Drugs _________________________________ 178
| | | | |
Chapter 35 - Men’s Health Drugs ___________________________________ 185
| | | | |
Chapter 36 - Antihistamines Decongestants Antitussives and Expectorants
| | | | | | |
| 189 Chapter 37 - Respiratory Drugs _________________________________ 194
| | | | |
Chapter 38 - Antibiotics Part 1 ______________________________________ 199
| | | | |
Chapter 39 - Antibiotics Part 2 ______________________________________ 206
| | | | |
Chapter 40 - Antiviral Drugs ________________________________________ 211
| | | |
Chapter 41 - Antitubercular Drugs ___________________________________ 216
| | | |
Chapter 42 - Antifungal Drugs ______________________________________ 221
| | | |
Chapter 43 - Antimalarial Antiprotozoal and Anthelmintic Drugs ____________ 226
| | | | | | |
Chapter 44 - Anti-inflammatory and Antigout Drugs _____________________ 231
| | | | | |
Chapter 45 - Antineoplastic Drugs Part 1 Cancer Overview and Cell
| | | | | | | | | |
| Cycle 236 Chapter 46 - Antineoplastic Drugs Part 2 Cell Cycle Nonspecific and
| | | | | | | | | | | |
| Misc.
Drugs _________________________________________________________ 242
Chapter 47 - Biologic Response–Modifying and Antirheumatic Drugs _______ 247
| | | | | | |
Chapter 48 - Immunosuppressant Drugs ______________________________ 252
| | | |
Chapter 49 - Immunizing Drugs _____________________________________ 257
| | | |
Chapter 50 - Acid-Controlling Drugs__________________________________ 262
| | | |
Chapter 51 - Bowel Disorder Drugs __________________________________ 268
| | | | |
Chapter 52 - Antiemetic and Antinausea Drugs ________________________ 275
| | | | | |
Chapter 53 - Vitamins and Minerals__________________________________ 280
| | | | |
Chapter 54 - Anemia Drugs ________________________________________ 286
| | | |
Chapter 55 - Nutritional Supplements ________________________________ 292
| | | |
Chapter 56 - Drugs _______________________________________________ 296
| | |
Chapter 57 - Ophthalmic Drugs _____________________________________ 302
| | | |
,Chapter 58 - Otic Drugs ___________________________________________ 307
| | | |
, 3
Chapter 01: The Nursing Process and Drug Therapy
| | | | | | |
Lilley: Pharmacology and the Nursing Process, 9th Edition
| | | | | | | |
MULTIPLE |CHOICE
1. The |nurse |is |developing |a |human |needs |statement |for |a |patient |who |has |a |new |diagnosis |of
|heart |failure. |Identification |of |human |needs |statements |occur |with |which |of |these
|activities?
a. Collection |of |patient |data
b. Administering |interventions
c. Deciding |on |patient |outcomes
d. Documenting |the |patient’s |behavior
ANS: | A
Identification |of |human |needs |occurs |with |the |collection |of |patient |data.
DIF: Cognitive |Level: |Understanding |(Comprehension)
|TOP: | Nursing |Process: |Human |Needs |Statement
MSC: | NCLEX: |Safe |and |Effective |Care |Environment: |Management |of |Care
2. The |patient |is |to |receive |oral |guaifenesin |(Mucinex) |twice |a |day. |Today, |the |nurse |was
|busy |and |gave |the |medication |2 |hours |after |the |scheduled |dose |was |due. |What |type
|of |problem |does |this |represent?
a. “Right |time”
b. “Right |dose”
c. “Right |route”
d. “Right |medication”
ANS: | A
“Right |time” |is |correct |because |the |medication |was |given |more |than |30 |minutes |after |the
|scheduled |dose |was |due. |“Dose” |is |incorrect |because |the |dose |is |not |related |to |the |time |the
|medication |administration |is |scheduled. |“Route” |is |incorrect |because |the |route |is |not
|affected. |“Medication” |is |incorrect |because |the |medication |ordered |will |not |change.
DIF: Cognitive |Level: |Applying |(Application)
|TOP: | Nursing |Process: |Implementation
MSC: | NCLEX: |Safe |and |Effective |Care |Environment: |Safety |and |Infection |Control
3. The |nurse |has |been |monitoring |the |patient’s |progress |on |a |new |drug |regimen |since |the
|first |dose |and |documenting |the |patient’s |therapeutic |response |to |the |medication. |Which
|phase |of |the |nursing |process |do |these |actions |illustrate?
a. Human |needs |statement
b. Planning
c. Implementation
d. Evaluation
ANS: | D
Monitoring |the |patient’s |progress, |including |the |patient’s |response |to |the |medication, |is
|part |of |the |evaluation |phase. |Planning, |implementation, |and |human |needs |statement |are |not
|illustrated |by |this |example.
Chapter |1 |- |The |Nursing |Process |and |Drug 3
|Therapy
| | | | | | | |
Chapter 2 - Pharmacologic Principles _________________________________ 7
| | | |
Chapter 3 - Lifespan Considerations _________________________________ 13
| | | |
Chapter 4 - Cultural Legal and Ethical Considerations ___________________ 19
| | | | | | |
Chapter 5 - Medication Errors Preventing and Responding _______________ 25
| | | | | | |
Chapter 6 - Patient Education and Drug Therapy _______________________ 29
| | | | | | |
Chapter 7 - Over-the-Counter Drugs and Herbal and Dietary
| | | | | | | |
| Supplements 34 | | Chapter 8 - Gene Therapy and Pharmacogenomics ____ 38 | | | | | |
Chapter 9 - Photo Atlas of Drug Administration ________________________ 42
| | | | | | |
Chapter 10 - Analgesic Drugs ______________________________________ 50
| | | |
Chapter 11 - General and Local Anesthetics ___________________________ 57
| | | | | |
Chapter 12 - Central Nervous System Depressants and Muscle
| | | | | | | |
| Relaxants 61 | | Chapter 13 - Central Nervous System Stimulants and Related
| | | | | | | |
| Drugs _________________________________________________________ 66
Chapter 14 - Antiepileptic Drugs ____________________________________ 70
| | | |
Chapter 15 - Anti-Parkinson Drugs___________________________________ 75
| | | |
Chapter 16 - Psychotherapeutic Drugs _______________________________ 80
| | | |
Chapter 17 - Substance Use Disorder ________________________________ 87
| | | | |
Chapter 18 - Adrenergic Drugs ______________________________________ 92
| | | |
Chapter 19 - Adrenergic-Blocking Drugs ______________________________ 97
| | | |
Chapter 20 - Cholinergic Drugs _____________________________________ 102
| | | |
Chapter 21 - Cholinergic-Blocking Drugs ______________________________ 107
| | | |
Chapter 22 - Antihypertensive Drugs _________________________________ 112
| | | |
Chapter 23 - Antianginal Drugs _____________________________________ 118
| | | |
Chapter 24 - Heart Failure Drugs ____________________________________ 124
| | | | |
Chapter 25 - Antidysrhythmic Drugs _________________________________ 129
| | | |
Chapter 26 - Coagulation Modifier Drugs ______________________________ 134
| | | | |
Chapter 27 - Antilipemic Drugs _____________________________________ 140
| | | |
Chapter 28 - Diuretic Drugs ________________________________________ 145
| | | |
Chapter 29 - Fluids and Electrolytes _________________________________ 151
| | | | |
,Chapter 30 - Pituitary Drugs ________________________________________ 157
| | | |
Chapter 31 - Thyroid and Antithyroid Drugs____________________________ 161
| | | | | |
Chapter 32 - Antidiabetic Drugs _____________________________________ 166
| | | |
Chapter 33 - Adrenal Drugs ________________________________________ 174
| | | |
Chapter 34 - Women’s Health Drugs _________________________________ 178
| | | | |
Chapter 35 - Men’s Health Drugs ___________________________________ 185
| | | | |
Chapter 36 - Antihistamines Decongestants Antitussives and Expectorants
| | | | | | |
| 189 Chapter 37 - Respiratory Drugs _________________________________ 194
| | | | |
Chapter 38 - Antibiotics Part 1 ______________________________________ 199
| | | | |
Chapter 39 - Antibiotics Part 2 ______________________________________ 206
| | | | |
Chapter 40 - Antiviral Drugs ________________________________________ 211
| | | |
Chapter 41 - Antitubercular Drugs ___________________________________ 216
| | | |
Chapter 42 - Antifungal Drugs ______________________________________ 221
| | | |
Chapter 43 - Antimalarial Antiprotozoal and Anthelmintic Drugs ____________ 226
| | | | | | |
Chapter 44 - Anti-inflammatory and Antigout Drugs _____________________ 231
| | | | | |
Chapter 45 - Antineoplastic Drugs Part 1 Cancer Overview and Cell
| | | | | | | | | |
| Cycle 236 Chapter 46 - Antineoplastic Drugs Part 2 Cell Cycle Nonspecific and
| | | | | | | | | | | |
| Misc.
Drugs _________________________________________________________ 242
Chapter 47 - Biologic Response–Modifying and Antirheumatic Drugs _______ 247
| | | | | | |
Chapter 48 - Immunosuppressant Drugs ______________________________ 252
| | | |
Chapter 49 - Immunizing Drugs _____________________________________ 257
| | | |
Chapter 50 - Acid-Controlling Drugs__________________________________ 262
| | | |
Chapter 51 - Bowel Disorder Drugs __________________________________ 268
| | | | |
Chapter 52 - Antiemetic and Antinausea Drugs ________________________ 275
| | | | | |
Chapter 53 - Vitamins and Minerals__________________________________ 280
| | | | |
Chapter 54 - Anemia Drugs ________________________________________ 286
| | | |
Chapter 55 - Nutritional Supplements ________________________________ 292
| | | |
Chapter 56 - Drugs _______________________________________________ 296
| | |
Chapter 57 - Ophthalmic Drugs _____________________________________ 302
| | | |
,Chapter 58 - Otic Drugs ___________________________________________ 307
| | | |
, 3
Chapter 01: The Nursing Process and Drug Therapy
| | | | | | |
Lilley: Pharmacology and the Nursing Process, 9th Edition
| | | | | | | |
MULTIPLE |CHOICE
1. The |nurse |is |developing |a |human |needs |statement |for |a |patient |who |has |a |new |diagnosis |of
|heart |failure. |Identification |of |human |needs |statements |occur |with |which |of |these
|activities?
a. Collection |of |patient |data
b. Administering |interventions
c. Deciding |on |patient |outcomes
d. Documenting |the |patient’s |behavior
ANS: | A
Identification |of |human |needs |occurs |with |the |collection |of |patient |data.
DIF: Cognitive |Level: |Understanding |(Comprehension)
|TOP: | Nursing |Process: |Human |Needs |Statement
MSC: | NCLEX: |Safe |and |Effective |Care |Environment: |Management |of |Care
2. The |patient |is |to |receive |oral |guaifenesin |(Mucinex) |twice |a |day. |Today, |the |nurse |was
|busy |and |gave |the |medication |2 |hours |after |the |scheduled |dose |was |due. |What |type
|of |problem |does |this |represent?
a. “Right |time”
b. “Right |dose”
c. “Right |route”
d. “Right |medication”
ANS: | A
“Right |time” |is |correct |because |the |medication |was |given |more |than |30 |minutes |after |the
|scheduled |dose |was |due. |“Dose” |is |incorrect |because |the |dose |is |not |related |to |the |time |the
|medication |administration |is |scheduled. |“Route” |is |incorrect |because |the |route |is |not
|affected. |“Medication” |is |incorrect |because |the |medication |ordered |will |not |change.
DIF: Cognitive |Level: |Applying |(Application)
|TOP: | Nursing |Process: |Implementation
MSC: | NCLEX: |Safe |and |Effective |Care |Environment: |Safety |and |Infection |Control
3. The |nurse |has |been |monitoring |the |patient’s |progress |on |a |new |drug |regimen |since |the
|first |dose |and |documenting |the |patient’s |therapeutic |response |to |the |medication. |Which
|phase |of |the |nursing |process |do |these |actions |illustrate?
a. Human |needs |statement
b. Planning
c. Implementation
d. Evaluation
ANS: | D
Monitoring |the |patient’s |progress, |including |the |patient’s |response |to |the |medication, |is
|part |of |the |evaluation |phase. |Planning, |implementation, |and |human |needs |statement |are |not
|illustrated |by |this |example.
Chapter |1 |- |The |Nursing |Process |and |Drug 3
|Therapy
